Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis

The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine

(2011) Rachel E. Laing et al.   CURRENT DRUG METABOLISM

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation

(2010) Nuala A. Helsby et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Paraoxonase-1 is a major determinant of clopidogrel efficacy

(2010) Heleen J Bouman et al.   NATURE MEDICINE

Irinotecan pharmacogenomics

(2010) Sharon Marsh et al.   PHARMACOGENOMICS

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics

(2010) Laurent Becquemont et al.   PHARMACOGENOMICS

Clinically Available Pharmacogenomics Tests

(2009) DA Flockhart et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold

(2008) Sharon J. Gardiner et al.   Clinical Gastroenterology and Hepatology

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease

(2008) Rebecca L Roberts et al.   Personalized Medicine